These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37986400)

  • 1. A review of functional pancreatic neuroendocrine tumors: Exploring the molecular pathogenesis, diagnosis and treatment.
    Alshareefy Y; Cummins S; Mazzoleni A; Sharma V; Guggilapu S; Leong AWY; Wireko AA
    Medicine (Baltimore); 2023 Nov; 102(46):e36094. PubMed ID: 37986400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.
    Park JK; Paik WH; Lee K; Ryu JK; Lee SH; Kim YT
    Oncotarget; 2017 Jul; 8(30):49796-49806. PubMed ID: 28591701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroendocrine pancreatic tumors: guidelines for management and update.
    Burns WR; Edil BH
    Curr Treat Options Oncol; 2012 Mar; 13(1):24-34. PubMed ID: 22198808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reprint of: The Diagnostic and Prognostic Utility of Incorporating DAXX, ATRX, and Alternative Lengthening of Telomeres (ALT) to the Evaluation of Pancreatic Neuroendocrine Tumors (PanNETs).
    Heaphy CM; Singhi AD
    Hum Pathol; 2023 Feb; 132():1-11. PubMed ID: 36702689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convergence between germline and somatic mutations in pancreatic neuroendocrine tumors.
    Ling C; Hong X; Xu M; Wang Y; Ma X; Cui Y; Jiang R; Cao D; Wu H; Tong A; Zhao Y; Wu W
    Eur J Endocrinol; 2022 May; 187(1):85-90. PubMed ID: 35521758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Significance of Altered ATRX/DAXX Gene in Pancreatic Neuroendocrine Tumors: A Meta-Analysis.
    Wang F; Xu X; Ye Z; Qin Y; Yu X; Ji S
    Front Endocrinol (Lausanne); 2021; 12():691557. PubMed ID: 34220718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size.
    Hackeng WM; Brosens LAA; Kim JY; O'Sullivan R; Sung YN; Liu TC; Cao D; Heayn M; Brosnan-Cashman J; An S; Morsink FHM; Heidsma CM; Valk GD; Vriens MR; Nieveen van Dijkum E; Offerhaus GJA; Dreijerink KMA; Zeh H; Zureikat AH; Hogg M; Lee K; Geller D; Marsh JW; Paniccia A; Ongchin M; Pingpank JF; Bahary N; Aijazi M; Brand R; Chennat J; Das R; Fasanella KE; Khalid A; McGrath K; Sarkaria S; Singh H; Slivka A; Nalesnik M; Han X; Nikiforova MN; Lawlor RT; Mafficini A; Rusev B; Corbo V; Luchini C; Bersani S; Pea A; Cingarlini S; Landoni L; Salvia R; Milione M; Milella M; Scarpa A; Hong SM; Heaphy CM; Singhi AD
    Gut; 2022 May; 71(5):961-973. PubMed ID: 33849943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnostic and prognostic utility of incorporating DAXX, ATRX, and alternative lengthening of telomeres to the evaluation of pancreatic neuroendocrine tumors.
    Heaphy CM; Singhi AD
    Hum Pathol; 2022 Nov; 129():11-20. PubMed ID: 35872157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications of cell-of-origin epigenetic characteristics in non-functional pancreatic neuroendocrine tumors.
    Dreijerink KM; Hackeng WM; Singhi AD; Heaphy CM; Brosens LA
    J Pathol; 2022 Feb; 256(2):143-148. PubMed ID: 34750813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
    François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Genetics and Genomic Data on Pancreatic Neuroendocrine Tumors: Implications for Diagnosis, Treatment, and Targeted Therapies.
    Schmitt AM; Marinoni I; Blank A; Perren A
    Endocr Pathol; 2016 Sep; 27(3):200-4. PubMed ID: 27456058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current understanding of the molecular biology of pancreatic neuroendocrine tumors.
    Zhang J; Francois R; Iyer R; Seshadri M; Zajac-Kaye M; Hochwald SN
    J Natl Cancer Inst; 2013 Jul; 105(14):1005-17. PubMed ID: 23840053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.
    Jiao Y; Shi C; Edil BH; de Wilde RF; Klimstra DS; Maitra A; Schulick RD; Tang LH; Wolfgang CL; Choti MA; Velculescu VE; Diaz LA; Vogelstein B; Kinzler KW; Hruban RH; Papadopoulos N
    Science; 2011 Mar; 331(6021):1199-203. PubMed ID: 21252315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors.
    Chou A; Itchins M; de Reuver PR; Arena J; Clarkson A; Sheen A; Sioson L; Cheung V; Perren A; Nahm C; Mittal A; Samra JS; Pajic M; Gill AJ
    Hum Pathol; 2018 Dec; 82():249-257. PubMed ID: 30081149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systems biology approach to define mechanisms, phenotypes, and drivers in PanNETs with a personalized perspective.
    Werle SD; Ikonomi N; Lausser L; Kestler AMTU; Weidner FM; Schwab JD; Maier J; Buchholz M; Gress TM; Kestler AMR; Kestler HA
    NPJ Syst Biol Appl; 2023 Jun; 9(1):22. PubMed ID: 37270586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetics of pancreatic neuroendocrine tumors: implications for the clinic.
    Pea A; Hruban RH; Wood LD
    Expert Rev Gastroenterol Hepatol; 2015; 9(11):1407-19. PubMed ID: 26413978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.
    Kim JY; Brosnan-Cashman JA; An S; Kim SJ; Song KB; Kim MS; Kim MJ; Hwang DW; Meeker AK; Yu E; Kim SC; Hruban RH; Heaphy CM; Hong SM
    Clin Cancer Res; 2017 Mar; 23(6):1598-1606. PubMed ID: 27663587
    [No Abstract]   [Full Text] [Related]  

  • 18. Study of clinicopathological features, hormone immunoexpression, and loss of ATRX and DAXX expression in pancreatic neuroendocrine tumors.
    Yadav R; Kakkar A; Sharma A; Malik PS; Sharma MC
    Scand J Gastroenterol; 2016 Aug; 51(8):994-9. PubMed ID: 27162024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiregion WES of metastatic pancreatic neuroendocrine tumors revealed heterogeneity in genomic alterations, immune microenvironment and evolutionary patterns.
    Jiang Y; Dong YH; Zhao SW; Liu DY; Zhang JY; Xu XY; Chen H; Chen H; Jin JB
    Cell Commun Signal; 2024 Mar; 22(1):164. PubMed ID: 38448900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advancements in pancreatic neuroendocrine tumors.
    Sadaria MR; Hruban RH; Edil BH
    Expert Rev Gastroenterol Hepatol; 2013 Jul; 7(5):477-90. PubMed ID: 23899286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.